Leipzig University (Sponsor)

Overview
Related items

For each clinical trial conducted according to the German Medicines Act (AMG) or the Medical Devices Act (MPG), a sponsor must be named who assumes overall responsibility for the clinical trial. In the case of human clinical trials initiated and managed by staff of the Medical Faculty of the University of Leipzig or Leipzig University Hospital (UKL) (Investigator Initiated Trials; IITs), the University of Leipzig assumes the function of sponsor if no third party is the sponsor.

Web page: https://www.uniklinikum-leipzig.de/wissenschaft-forschung/forschungs-administration/klinische-studien

Funding details:

No funding details specified

Related items

Showing 5 out of a possible 12 People Advanced People list for this Sponsor with search and filtering

Prof. Dr. med. Thomas Berg

Trial Projects:

GRAFT: Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure

Institutions: Universitätsklinikum Leipzig, Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

https://orcid.org/0000-0003-0003-6241

Dr. Oana Brosteanu

Trial Projects:

Institutions: Zentrum für Klinische Studien Leipzig (ZKS Leipzig), Universität Leipzig

https://orcid.org/0000-0002-8706-217X

PD Dr. Jens Bräunlich

Trial Projects:

TIBICO: Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients

Institutions: Universitätsklinikum Leipzig, Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

https://orcid.org/0000-0002-9669-0899

Xiaoming Hu

Trial Projects:

STOP-NUC: A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response

Institutions: Zentrum für Klinische Studien Leipzig (ZKS Leipzig), Universität Leipzig

René Hänsel

Trial Projects:

Institutions: Zentrum für Klinische Studien Leipzig (ZKS Leipzig), Universität Leipzig, Default Institution

https://orcid.org/0000-0001-8344-0658

View all 12 People

Showing 5 out of a possible 6 Trial Projects Advanced Trial Projects list for this Sponsor with search and filtering

STOP-NUC: A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response

Coordinating investigator: Prof. Dr. Florian van Bömmel Sektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Sponsor: Universität Leipzig Ritterstr. 26, 04109 Leipzig Registration: EudraCT: 2013-004882-15 DRKS: DRKS00006240

Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg -negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. Discontinuation of NUC treatment ...

Sponsor: Leipzig University (Sponsor)

Public web page: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004882-15/DE

Start date: 18th Nov 2014

End date: 30th Jan 2022

BASALIT: Birch Associated Soy Allergy and Immuno-Therapy

A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy (Birch Associated Soy Allergy and Immuno-Therapy)

Coordinating investigators: Prof. Dr. Jan C. Simon Prof. Dr. Regina Treudler Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig ...

Sponsor: Leipzig University (Sponsor)

Public web page: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011737-27/DE

End date: 18th Jul 2014

GRAFT: Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure

Coordinating investigator: Prof. Dr. Thomas Berg Sektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig
Sponsor: Universität Leipzig Ritterstr. 26, 04109 Leipzig
Registration: EudraCT: 2015-002212-32 ClinicalTrials.gov: NCT02669680

Sponsor: Leipzig University (Sponsor)

Public web page: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002212-32/DE

TIBICO: Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients

Studienleitung: Prof. Dr. med. Hubert WirtzDr. med. Jens Bräunlich Universität Leipzig Department Innere Medizin, Neurologie und Dermatologie Abteilung für Pneumologie\ Registration: clinicaltrials.gov: NCT02007772

Sponsor: Leipzig University (Sponsor)

Public web page: https://clinicaltrials.gov/ct2/show/record/NCT02007772?term=NCT02007772

AbCD: Antibody diagnostics in paediatric Coeliac Disease

Ziel der Studie ist es für Kinder, bei denen ein Verdacht auf eine Zöliakieerkrankung besteht, ein neues Verfahren zur Auswertung von Antikörpertests zu entwickeln, so dass die Diagnose über Antikörpertests eindeutiger ausfällt und in klaren Fällen eine Biopsie für die endgültige Diagnose nicht mehr erforderlich ist. Bei den Antikörpertests, die in der Studie verwendet werden, handelt es sich um CE-zertifizierte Medizinprodukte. Das bedeutet, dass diese Tests für den in der Studie vorgesehenen ...

Sponsor: Leipzig University (Sponsor)

Public web page: https://drks.de/search/de/trial/DRKS00003854

Start date: 18th Oct 2012

End date: 30th Jul 2016

View all 6 Trial Projects

Showing 5 out of a possible 6 Institutions Advanced Institutions list for this Sponsor with search and filtering

Default Institution

Country: United Kingdom

City: Not specified

Web page: Not specified

Universitätsklinikum Leipzig, Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik

Country: Germany

City: Leipzig

Web page: https://www.uniklinikum-leipzig.de/einrichtungen/labormedizin

Universitätsklinikum Leipzig, Klinik und Poliklinik für Anästhesiologie und Intensivtherapie

Country: Germany

City: Leipzig

Web page: https://www.uniklinikum-leipzig.de/einrichtungen/kai

Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie

Country: Germany

City: Leipzig

Web page: https://www.uniklinikum-leipzig.de/einrichtungen/dermatologie

Universitätsklinikum Leipzig, Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

Country: Germany

City: Leipzig

Web page: https://www.uniklinikum-leipzig.de/einrichtungen/medizinische-klinik-2/hepatologie

View all 6 Institutions

Advanced Data files list for this Sponsor with search and filtering

BASALIT Example Data File

BASALIT: Birch Associated Soy Allergy and Immuno-Therapy

Just synthetic data from - no relation to BASALIT. Just Placeholder to show how data files can be explored in LDH.

Creator: Dr. Frank Meineke

Submitter: Dr. Frank Meineke

Created: 3rd Apr 2023 at 15:58, Last updated: 21st Oct 2024 at 12:05

Showing 5 out of a possible 8 Publications Advanced Publications list for this Sponsor with search and filtering

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.

(Show All)

Abstract (Expand)

BACKGROUND & AIMS: Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. … Discontinuation of NUC treatment may lead to functional cure; however, to date, the evidence for this has been based on small or non-randomized clinical trials. The STOP-NUC trial was designed with the aim of increasing the HBsAg loss rate using a NUC treatment interruption approach. METHODS: In this multicenter, randomized-controlled trial, 166 HBeAg-negative patients with chronic hepatitis B on continuous long-term NUC treatment, with HBV DNA <172 IU/ml (1,000 copies/ml) for >/=4 years, were randomized to either stop (Arm A) or continue NUC treatment (Arm B) for a 96-week observation period. In total, 158 patients were available for final analysis, 79 per arm. The primary endpoint was sustained HBsAg loss up to week 96. RESULTS: Our study met its primary objective by demonstrating HBsAg loss in eight patients (10.1%, 95% CI 4.8%-19.5%) in Arm A and in no patient in Arm B (p = 0.006). Among patients with baseline HBsAg levels <1,000 IU/ml, seven (28%) achieved HBsAg loss. In Arm A, re-therapy was initiated in 11 (13.9%) patients, whereas 32 (40.5%) patients achieved sustained remission. A decrease of HBsAg >1 log IU/ml was observed in 16 patients (20.3%) in Arm A and in one patient (1.3%) in Arm B. No serious adverse events related to treatment cessation occurred. CONCLUSIONS: Cessation of NUC treatment was associated with a significantly higher rate of HBsAg loss than continued NUC treatment, which was largely restricted to patients with end of treatment HBsAg levels <1,000 IU/ml. IMPACT AND IMPLICATIONS: As HBeAg-negative patients with chronic hepatitis B on nucleos(t)ide analogues (NUCs) rarely achieve functional cure, treatment is almost always lifelong. The STOP-NUC trial was conducted to investigate whether discontinuing long-term NUC treatment can increase the cure rate. We found that some patients achieved functional cure after stopping NUCs, which was especially pronounced in patients with HBsAg levels <1,000 at the end of NUC treatment, and that many did not need to resume therapy. The results of the Stop-NUC trial provide evidence for the concept of stopping NUC treatment as a therapeutic option that can induce functional cure.

Authors: F. van Bommel, K. Stein, R. Heyne, J. Petersen, P. Buggisch, C. Berg, S. Zeuzem, A. Stallmach, M. Sprinzl, E. Schott, A. Pathil-Warth, U. von Arnim, V. Keitel, J. Lohmeyer, K. G. Simon, C. Trautwein, A. Trein, D. Huppe, M. Cornberg, F. Lammert, P. Ingiliz, R. Zachoval, H. Hinrichsen, A. Zipprich, H. Klinker, J. Schulze Zur Wiesch, A. Schmiedeknecht, O. Brosteanu, T. Berg

Date Published: 18th Apr 2023

Publication Type: Journal

PubMed ID: 37062574

Citation: J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28.

Created: 22nd Aug 2023 at 14:31

Peptide epitopes as biomarkers of soya sensitization in rBet v 1 immunotherapy of birch-related soya allergy.

BASALIT: Birch Associated Soy Allergy and Immuno-Therapy

Abstract (Expand)

BACKGROUND: There are no diagnostic and/or prognostic markers of the treatment outcome in patients receiving allergen immunotherapy (AIT). Although numerous allergen epitopes are known, their value in …

Authors: L. R. Caballero, R. Treudler, N. Delaroque, J. C. Simon, K. Kern, M. Szardenings

Date Published: 15th Sep 2022

Publication Type: Journal

PubMed ID: 36102274

Citation: Clin Exp Allergy. 2023 Mar;53(3):316-326. doi: 10.1111/cea.14224. Epub 2022 Sep 23.

Created: 21st Oct 2024 at 11:55

Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).

GRAFT: Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure

Abstract (Expand)

BACKGROUND & AIMS: Based on positive results from small single center studies, granulocyte-colony stimulating factor (G-CSF) is being widely used for the treatment of patients with acute-on-chronic … liver failure (ACLF). Herein, we aimed to evaluate the safety and efficacy of G-CSF in patients with ACLF. METHODS: In this multicenter, prospective, controlled, open-label phase II study, 176 patients with ACLF (EASL-CLIF criteria) were randomized to receive G-CSF (5 mug/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n = 88) or SMT alone. The primary efficacy endpoint was 90-day transplant-free survival analyzed by Cox regression modeling. The key secondary endpoints were overall and transplant-free survival after 360 days, the development of ACLF-related complications, and the course of liver function scores during the entire observation period. RESULTS: Patients treated with G-CSF had a 90-day transplant-free survival rate of 34.1% compared to 37.5% in the SMT group (hazard ratio [HR] 1.05; 95% CI 0.711-1.551; p = 0.805). Transplant-free and overall survival at 360 days did not differ between the 2 arms (HR 0.998; 95% CI 0.697-1.430; p = 0.992 and HR 1.058; 95% CI 0.727-1.548; p = 0.768, respectively). G-CSF did not improve liver function scores, the occurrence of infections, or survival in subgroups of patients without infections, with alcohol-related ACLF, or with ACLF defined by the APASL criteria. Sixty-one serious adverse events were reported in the G-CSF+SMT group and 57 were reported in the SMT group. In total, 7 drug-related serious adverse reactions occurred in the G-CSF group. The study was prematurely terminated due to futility after conditional power calculation. CONCLUSIONS: In contrast to previous findings, G-CSF had no significant beneficial effect on patients with ACLF in this multicenter controlled trial, which suggests that it should not be used as a standard treatment for ACLF. CLINICALTRIALS. GOV NUMBER: NCT02669680 LAY SUMMARY: Granulocyte-colony stimulating factor was considered as a novel treatment for acute-on-chronic liver failure (ACLF). We performed the first randomized, multicenter, controlled phase II trial, which showed that G-CSF did not improve survival or other clinical endpoints in patients with ACLF. Therefore, G-CSF should not be used to treat liver disease outside clinical studies.

Authors: C. Engelmann, A. Herber, A. Franke, T. Bruns, P. Reuken, I. Schiefke, A. Zipprich, S. Zeuzem, T. Goeser, A. Canbay, C. Berg, J. Trebicka, F. E. Uschner, J. Chang, T. Mueller, N. Aehling, M. Schmelzle, K. Splith, F. Lammert, C. M. Lange, C. Sarrazin, C. Trautwein, M. Manns, D. Haussinger, J. Pfeiffenberger, P. R. Galle, A. Schmiedeknecht, T. Berg

Date Published: 9th Aug 2021

Publication Type: Journal

PubMed ID: 34364917

Citation: J Hepatol. 2021 Dec;75(6):1346-1354. doi: 10.1016/j.jhep.2021.07.033. Epub 2021 Aug 5.

Created: 25th Jan 2024 at 07:49

Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

TIBICO: Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients

Abstract (Expand)

BACKGROUND: Despite the encouraging results of noninvasive ventilation (NIV) in chronic hypercapnic COPD patients, it is also evident that some patients do not tolerate NIV or do not benefit from it. …

Authors: J. Braunlich, D. Dellweg, A. Bastian, S. Budweiser, W. Randerath, D. Triche, M. Bachmann, C. Kahler, A. H. Bayarassou, I. Mader, J. Geiseler, N. Kohler, D. Petroff, H. Wirtz

Date Published: 17th Jul 2019

Publication Type: Journal

PubMed ID: 31308647

Citation: Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1411-1421. doi: 10.2147/COPD.S206111. eCollection 2019.

Created: 25th Jan 2024 at 07:38

Individualized positive end-expiratory pressure in obese patients during general anaesthesia: a randomized controlled clinical trial using electrical impedance tomography.

ADIPO-Vent: Optimierung der perioperativen maschinellen Ventilation bei adipösen und normalgewichtigen Patienten durch PEEP-Titration anhand der Elektrischen Impedanz-Tomografie

Abstract (Expand)

BACKGROUND: General anaesthesia leads to atelectasis, reduced end-expiratory lung volume (EELV), and diminished arterial oxygenation in obese patients. We hypothesized that a combination of a recruitment …

Authors: C. Nestler, P. Simon, D. Petroff, S. Hammermuller, D. Kamrath, S. Wolf, A. Dietrich, L. M. Camilo, A. Beda, A. R. Carvalho, A. Giannella-Neto, A. W. Reske, H. Wrigge